Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma

Endocrine-Related Cancer

Volumn 12, Issue 2, 2005, Pages 263-272

  Brouwers, F M ^a   Petricoin III, E F ^b   Ksinantova, L ^c   Breza, J ^d   Rajapakse, V ^e   Ross, S ^e   Johann, D ^e   Mannelli, M ^f   Shulkin, B L ^g   Kvetnansky, R ^c   Eisenhofer, G ^h   Walther, M M ^e   Hitt, B A ⁱ   Conrads, T P ^j   Veenstra, T D ^j   Mannion, D P ^k   Wall, M R ^k   Wolfe, G M ^k   Fusaro, V A ^e   Liotta, L A ^e   Pacak, K ^a   more..

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^d Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF FLORENCE   (Italy)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

ⁱ National Institutes of Health ^*  (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

^k Predictive Diagnostics Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOME;

ADOLESCENT; ADULT; AGED; ALGORITHM; ANALYTIC METHOD; ARTICLE; BENIGN TUMOR; BIOINFORMATICS; CHILD; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METASTASIS; PHEOCHROMOCYTOMA; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TUMOR LOCALIZATION;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; CHILD; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PHEOCHROMOCYTOMA; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 21244484643     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00913     Document Type: Article

References (36)

1. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z et al. 2002 Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Research 62 3609-3614.
2. Aebersold R & Mann M 2003 Mass spectrometry-based proteomics. Nature 422 198-207.
3. Brown HM, Komorowski RA, Wilson SD, Demeure MJ & Zhu YR 1999 Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: a positive correlation between MIB-1 staining and malignant tumor behavior. Cancer 86 1583-1589.
4. Clarke W, Silverman BC, Zhang Z, Chan DW, Klein AS & Molmenti EP 2003 Characterization of renal allograft rejection by urinary proteomic analysis. Annals of Surgery 237 660-664.
5. Conrads TP, Fusaro VA, Ross S, Johann D, Rajapakse V, Hitt BA, Steinberg SM, Kohn EC, Fishman DA, Whitely G et al. 2004 High-resolution serum proteomic features for ovarian cancer detection. Endocrine-Related Cancer 11 163-178.
6. Dannenberg H, Speel EJ, Zhao J, Saremaslani P, van Der Harst E, Roth J, Heitz PU, Bonjer HJ, Dinjens WN, Mooi WJ et al. 2000 Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. American Journal of Pathology 157 353-359.
7. Edstrom E, Mahlamaki E, Nord B, Kjellman M, Karhu R, Hoog A, Goncharov N, Teh BT, Backdahl M & Larsson C 2000 Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. American Journal of Pathology 156 651-659.
8. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G & Hartwell L 2003 The case for early detection. Nature Reviews Cancer 3 243-252.
9. Goldstein DS, Stull R, Eisenhofer G, Sisson JC, Weder A, Averbuch SD & Keiser HR 1986 Plasma 3,4-dihydroxyphenylalanine (dopa) and catecholamines in neuroblastoma or pheochromocytoma. Annals of Internal Medicine 105 887-888.
10. Goldstein RE, O'Neill JA Jr, Holcomb GW 3rd, Morgan WM 3rd, Neblett WW 3rd, Gates JA, Brown N, Nadeau J, Smith B, Page DL et al. 1999 Clinical experience over 48 years with pheochromocytoma. Annals of Surgery 229 755-764.
11. Grizzle WE & Meleth S 2004 Clarification in the point/counterpoint discussion related to surface-enhanced laser desorption/ionization time-of-flight mass spectrometric identification of patients with adenocarcinomas of the prostate. Clinical Chemistry 50 1475-1477.
12. Hingorani SR, Petricoin III EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA et al. 2003 Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4 437-450.
13. John H, Ziegler WH, Hauri D & Jaeger P 1999 Pheochromocytomas: can malignant potential be predicted? Urology 53 679-683.
14. Kebebew E & Duh QY 1998 Benign and malignant pheochromocytoma: diagnosis, treatment, and follow-up. Surgical and Oncology Clinics of North America 7 765-789.
15. de Krijger RR, van der Harst E, van der Ham F, Stijnen T, Dinjens WN, Koper JW, Bruining HA, Lamberts SW & Bosman FT 1999 Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. Journal of Pathology 188 51-55.
16. Le Naour F, Misek DE, Krause MC, Deneux L, Giordano TJ, Scholl S & Hanash SM 2001 Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clinical Cancer Research 7 3328-3335.
17. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS & Eisenhofer G 2002 Biochemical diagnosis of pheochromocytoma: which test is best? Journal of the American Medical Association 287 1427-1434.
18. Li J, Zhang Z, Rosenzweig J, Wang YY & Chan DW 2002 Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clinical Chemistry 48 1296-1304.
19. Linnoila RI, Keiser HR, Steinberg SM & Lack EE 1990 Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Human Pathology 21 1168-1180.
20. Liotta LA, Ferrari M & Petricoin E 2003 Clinical proteomics: written in blood. Nature 425 905.
21. Mehta AI, Ross S, Lowenthal MS, Fusaro V, Fishman DA, Petricoin EF 3rd & Liotta LA 2003 Biomarker amplification by serum carrier protein binding. Disease Markers 19 1-10.
22. O'Riordain DS, Young WF Jr, Grant CS, Carney JA & van Heerden JA 1996 Clinical spectrum and outcome of functional extraadrenal paraganglioma. World Journal of Surgery 20 916-921.
23. Orlando C & Gelmini S 2001 Telomerase in endocrine and endocrine-dependent tumors. Journal of Steroid Biochemistry and Molecular Biology 78 201-214.
24. Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, Veenstra TD, Liotta LA & Petricoin EF 3rd 2004 Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. Journal of Urology 172 1302-1305.
25. Pacak K, Linehan WM, Eisenhofer G, Walther MM & Goldstein DS 2001a Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Annals of Internal Medicine 134 315-329.
26. Pacak K, Chrousos GP, Koch CA, Lenders JW & Eisenhofer G 2001b Pheochromocytoma: progress in diagnosis, therapy, and genetics. In Adrenal Disorders, edn 1, pp 479-523. Eds A Margioris & GP Chrousos. Totowa: Humana Press.
27. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC et al. 2002a Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 572-577.
28. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K et al. 2002b Serum proteomic patterns for detection of prostate cancer. Journal of the National Cancer Institute 94 1576-1578.
29. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ & Wright GL Jr 2002 Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clinical Chemistry 48 1835-1843.
30. Rao F, Keiser HR & O'Connor DT 2002 Malignant and benign pheochromocytoma: chromaffin granule transmitters and the response to medical and surgical treatment. Annals of the New York Academy of Sciences 971 530-532.
31. Rui Z, Jian-Guo J, Yuan-Peng T, Hai P & Bing-Gen R 2003 Use of serological proteomic methods to find biomarkers associated with breast cancer. Proteomics 3 433-439.
32. Sinz A, Bantscheff M, Mikkat S, Ringel B, Drynda S, Kekow J, Thiesen HJ & Glocker MO 2002 Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis. Electrophoresis 23 3445-3456.
33. Tanaka S, Ito T, Tomoda J, Higashi T, Yamada G & Tsuji T 1993 Malignant pheochromocytoma with hepatic metastasis diagnosed 20 years after resection of the primary adrenal lesion. Internal Medicine 32 789-794.
34. Vytvytska O, Nagy E, Bluggel M, Meyer HE, Kurzbauer R, Huber LA & Klade CS 2002 Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics 2 580-590.
35. Wadsworth JT, Somers KD, Cazares LH, Malik G, Adam BL, Stack BC Jr, Wright GL Jr & Semmes OJ 2004 Serum protein profiles to identify head and neck cancer. Clinical Cancer Research 10 1625-1632.
36. Wulfkuhle JD, Liotta LA & Petricoin EF 2003 Proteomic applications for the early detection of cancer. Nature Reviews Cancer 3 267-275.